This is in response to a very challenging environment. I would expect broader cuts to be announced within the sales force, marketing, general and (administration) as well as R&D over the longer run.

Within this tough environment, we generated a meaningful increase in overall revenue versus last quarter based on strong sales in consumer and commercial PCs and digital imaging products, as well as exceptional growth in outsourcing.

The educational environment I felt was compromised.

Approximately 50% of the cases are filed in the federal court, where standards for scientific evidence are far more rigorous.

Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.

Recent launches have significantly larger commercial potential than the previous cycle?and [are] likely to drive improving growth prospects post-2006.